ELUCIREM's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8114863 | GUERBET | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging |
Sep, 2028
(4 years from now) | |
| US10973934 | GUERBET | Gadolinium bearing PCTA-based contrast agents |
Aug, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590246 | GUERBET | Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process |
Jan, 2040
(15 years from now) | |
Elucirem is owned by Guerbet.
Elucirem contains Gadopiclenol.
Elucirem has a total of 3 drug patents out of which 0 drug patents have expired.
Elucirem was authorised for market use on 21 September, 2022.
Elucirem is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Elucirem from 21 September, 2026.
The generics of Elucirem are possible to be released after 17 January, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2027 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: 21 September, 2026
Market Authorisation Date: 21 September, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
ELUCIREM family patents
